Ihmettelin miksi tämä nousee kun huono tulos mutta ilmeisesti redeye arvioi tämän vuoden kasvun todella hulppeaksi ja jos marginaalit pysyy samoina niin onhan tämä kova.
2 Likes
Alkaa lähteä kyllä lapasesta hinnoittelu nyky-ympäristössä. Redeyen dcf mallissa käytetty 8,5% waccia ja terminaali on 55SEK/osake.
Onko näillä niin kestävä kilpailuetu että tuo on perusteltavissa? Ala on vaikea ymmärtää syvällisesti.
2 Likes
Genovis ottaa lisävauhtia suunnatessaan Kiinan markkinoille yhteistyöllä norjalaisen ArticZymesin kanssa. Genovista seuraava Redeye ensiarviossaan liehuttaa kannustavaa viiriä Genovikselle. Pörssissä Mr.Markkina myös positiivisia viboja osoittaa.
15 Likes
Vahvaa menoa
15 Likes
Kiinan markkinoille tähtääminen aiheuttaa meikäläiselle kylmiä väristyksiä. Onko tiedossa ketään/mitään yhtiötä joka on onnistuneesti ottanut Kiinan markkinoita haltuunsa? Ettei vaan kävisi niin että satsataan kovasti ja lopulta osaaminen ja tieto siirtyy yllättäen kiinalaisten haltuun…
3 Likes
Myin laput aiemmin, nyt tärähti 55sek hintahälytys. Ehkä mukaan uudestaan. Q1 oli älytön, toki selectan vaikutus iso. Markkina näemmä osasi jo odottaa hyvää tulosta. Redeye nosti waccin 9,5%aan ja sääti hieman ennusteita päätyen nostamaan peruscasen 91 SEKkiin.
2 Likes
Infinitely strong: https://mb.cision.com/Main/1712/3820614/2247306.pdf
With these numbers, it should be a hundred-euro stock, continues as the largest in my portfolio, nice to be along for the ride 
Edit: Growth continues into the distant future
10 Likes
There’s still quite a multiple to digest there; is the P/E for this year something in the range of 35–40 excluding capital gains?
1 Like
Gross Margin: 88%
Profit Margin: 54%
ROIC: 27.5%
Earnings Growth: approx. 30% (recurring services)
On top of these, the licensing business comes as a bonus.
It’s quite hard to find a better business. In the States, this would be valued muuuuch higher. Growth continues… choo choo 
12 Likes
That’s true, I jumped out myself at 70 SEK prices, but thanks to the SEK exchange rate, this would be quite a strong stock to buy back.
How do you see growth continuing in 2024-2025?
1 Like
Short-term share price movement is hard to predict as we know, but in the interim report, the CEO said that strong demand is continuing in Q3.
I don’t see any reasons why growth wouldn’t continue in the future; of course, there will be variation between quarters.
I’m not a TA expert, but if you look at the share price development over the longer term, we’re on an upward trend line from which we’ve bounced upwards so far. So, according to the trend, the rise would continue…
Edit: The wildcard for 2024–2026 is that licensing business. It could bring in millions to tens of millions of dollars as a bonus. Plus royalties after that if the drug reaches the market..
7 Likes
@DayTraderXL could perhaps chew on this in the right thread; to me, 42.50 looks like a relatively strong support area, so now could be a good time to buy with stops below 42.50. On a daily level, we’ve been trading in a range all year without any major trends.
3 Likes
Has RedEye made any report yet? I don’t have an account myself.
b9ec5758-e3be-3015-890f-8422917017d6.pdf (605,0 Kt)
Edit: Redeyen Base Case 95 SEK
7 Likes
I accidentally came across this:
It’s strange that Genovis itself hasn’t announced this, as it’s quite a large block. Lönn, after all, sits on the board and is the largest shareholder.
Well, it wasn’t exactly a massive dump relative to the total holding, and on the other hand, it might be good that one man’s ownership is diluted a bit. Unfortunately, I couldn’t find information on where the shares went. Hopefully to a hungry investor/partner.
Otherwise, Geno’s momentum seems very strong. New products are coming and sales are holding up despite the macro environment. Also, bioprocesses remain in the customer’s portfolio despite cost-cutting measures.
8 Likes
11 Likes
Geno’s interim report. 31% growth.
15 Likes
The market reaction is an overreaction IMO, I’m considering returning as a shareholder. The antibody business will still grow significantly and fuel enzyme sales at the same time.
2 Likes
I can’t remember the last time this stock went up on earnings day. It’s always a -15% hit. You make a nice profit by always buying after earnings and selling the day before.
1 Like
10 Likes